GSK plc
Biotech Investor · 2 portfolio companies
Portfolio
2
Combined Value
$1.6B
Focus Areas
3
Top Stage
Phase 2
Investment Focus
Portfolio Companies
| Company | Valuation |
|---|---|
| Nurix Therapeutics | $1.6B |
| ViiV Healthcare | — |
Biotech Investor · 2 portfolio companies
| Company | Valuation |
|---|---|
| Nurix Therapeutics | $1.6B |
| ViiV Healthcare | — |